Year Founded
2003
Ownership
Public
Employees
~50
Therapeutic Areas
Oncology
Stage
Commercial
Modalities
Autologous cell therapyAntibody-based immunotherapy

Apeiron Biologics General Information

APEIRON Biologics successfully developed QARZIBA® (dinutuximab beta), a monoclonal antibody for high-risk neuroblastoma, which is commercially available in over 35 countries. The company has also spun off its early-stage immuno-oncology portfolio into invIOs Holding AG.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Vienna,
Austria

Drug Pipeline

dinutuximab beta
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Apeiron Biologics's pipeline data

Book a demo

Key Partnerships

Recordati S.p.A., BeiGene, Ltd., invIOs Holding AG

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Apeiron Biologics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Apeiron Biologics's complete valuation and funding history, request access »